CREDIT SUISSE AG/ - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 36 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
CREDIT SUISSE AG/ ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2020$421,000
+84.6%
587,000
+119.0%
0.00%
Q1 2020$228,000
-96.3%
268,000
-94.3%
0.00%
-100.0%
Q4 2019$6,224,000
+142.0%
4,704,000
+81.0%
0.01%
+150.0%
Q2 2019$2,572,0002,599,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2020
NameSharesValueWeighting ↓
Worth Venture Partners, LLC 5,814,000$5,191,0003.20%
DLD Asset Management, LP 12,500,000$11,219,0000.70%
Senvest Management, LLC 5,000,000$4,345,0000.51%
Context Capital Management, LLC 985,000$863,0000.49%
LINDEN ADVISORS LP 30,755,000$26,983,0000.48%
SSI INVESTMENT MANAGEMENT LLC 5,896,000$5,014,0000.44%
BOOTHBAY FUND MANAGEMENT, LLC 4,386,000$3,812,0000.32%
ADVENT CAPITAL MANAGEMENT /DE/ 16,582,000$14,449,0000.31%
CSS LLC/IL 3,825,000$3,410,0000.27%
Polar Asset Management Partners Inc. 13,000,000$11,372,0000.23%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders